Abstract Background To analyze the clinical characteristics and chemo-resistance related factors of patients with resistant and non-resistant endometriosis-associated ovarian cancer (ovarian clear cell carcinoma and endometrioid carcinoma) by reviewing the data of epithelial ovarian cancer patients who received initial treatment in our hospital over a 12-year period. Results Among the 304 patients, 17.1% were seen with platinum-based drug resistance. The ROC curve of continuous variables was drawn according to resistance situation, then they were grouped by age (< 48 or ≥ 48 years), tumor size (< 7 cm or ≥ 7 cm) and Ca125 (< 90 and ≥ 90 U/ml). In univariate analysis, age ≥ 48 years, initial symptom of abdominal distension or weight loss, abnormal preoperative serum Ca125, Ca125 < 90 U/ml, advanced FIGO stage, absence of endometriosis, bilateral tumors, lack of lymphadenectomy, positive lymph nodes, unsatisfactory initial cytoreduction surgery and history of breast cancer were all related to drug resistance in ovarian cancer. In multivariate analysis, advanced stage, lack of lymphadenectomy, positive lymph nodes and history of breast cancer were independent risk factors related to platinum-based drug resistance (P < 0.05). Conclusion For patients of endometriosis-related ovarian cancer, platinum-based drug resistance were associated with advanced FIGO stage, lack of lymphadenectomy, positive lymph nodes and history of breast cancer.
展开▼
机译：摘要背景，通过审查在我们的初始治疗初始治疗的上皮卵巢癌患者的数据来分析抗性和无抗性子宫内膜病相关卵巢癌患者（卵巢透明细胞癌和子宫内膜瘤）患者的临床特征和化学抗性。医院超过12年。结果在304例患者中，铂族抗药性耐药地区均为17.1％。连续变量的ROC曲线根据阻力情况绘制，然后按年龄（<48或≥48岁），肿瘤大小（<7cm或≥7cm）和CA125（<90和≥90u / mL为分组）。在单变量分析中，年龄≥48岁，腹胀或减肥的初始症状，术前异常血清Ca125，Ca125 <90 U / ml，高级Figo阶段，缺乏子宫内膜异位症，双侧肿瘤，缺乏淋巴结切除术，阳性淋巴结，不令人满意初始细胞诊断手术和乳腺癌的历史均与卵巢癌的耐药性有关。在多变量分析中，晚期阶段，缺乏淋巴结切除术，乳腺癌阳性淋巴结和历史是与铂类药物抗性相关的独立危险因素（P <0.05）。结论针对子宫内膜异位症相关卵巢癌的患者，基于铂类药物抗性与先进的FIGO阶段相关，缺乏淋巴结切除术，阳性淋巴结和乳腺癌病史。
展开▼
